• Mark Terry
• 15 Apr, 2020

TScan Therapeutics, based in Waltham, Massachusetts, entered a collaboration agreement with Novartis. They will partner to discover and develop novel T-cell Receptor (TCR)-engineered T-cell therapies for solid tumors. Under the terms of the deal, Novartis is paying TScan an upfront technology access fee and research funding totaling $30 million. There are also milestone payments that could reach hundreds of millions of dollars.
Read more...